Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 15/20 | 0.82 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.66 |
| ▸ | FYN | P06241 | 3/20 | 0.66 |
| ▸ | SRC | P12931 | 3/20 | 0.66 |
| ▸ | ABL1 | P00519 | 3/20 | 0.66 |
| ▸ | EGFR | P00533 | 2/20 | 0.66 |
| ▸ | YES1 | P07947 | 2/20 | 0.66 |
| ▸ | LYN | P07948 | 2/20 | 0.66 |
| ▸ | HCK | P08631 | 2/20 | 0.66 |
| ▸ | KIT | P10721 | 2/20 | 0.66 |
| ▸ | BCR | P11274 | 2/20 | 0.66 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.66 |
| ▸ | FGR | P09769 | 1/20 | 0.66 |
| ▸ | JAK3 | P52333 | 1/20 | 0.66 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.66 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.66 |
| ▸ | SIK1 | P57059 | 1/20 | 0.63 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.63 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL773124 | 0.90 | LCK (1.00) | LCKMAPK14FYNSRCABL1 | |
| SCHEMBL31634947 | 0.90 | LCK (1.00) | LCKMAPK14FYNSRCABL1 | |
| SCHEMBL19390257 | 0.89 | LCK (0.82) | LCKMAPK14FYNSRCABL1 | |
| SCHEMBL774162 | 0.86 | LCK (1.00) | LCKMAPK14FYNSRCABL1 | |
| SCHEMBL14569078 | 0.85 | LCK (0.65) | LCKMAPK14FYNSRCABL1 | |
| SCHEMBL12454868 | 0.85 | LCK (0.76) | LCKMAPK14FYNSRCABL1 | |
| SCHEMBL1704678 | 0.85 | LCK (0.90) | LCKMAPK14FYNSRCABL1 | |
| SCHEMBL773654 | 0.85 | LCK (0.91) | LCKMAPK14FYNSRCABL1 | |
| SCHEMBL775144 | 0.85 | LCK (0.66) | LCKMAPK14FYNSRCABL1 | |
| SCHEMBL774308 | 0.85 | LCK (0.85) | LCKMAPK14FYNSRCABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308833-A2 | Cyclic protein tyrosine kinase inhibitors | Bristol-Myers Squibb Company (US) | 2011-04-13 | — | — | EP | claimed |
| EP-1758564-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | Brystol-Myers Squibb Company (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2005094376-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-13 | — | — | WO | claimed |
| US-20040209930-A1 | Synergistic methods and compositions for treating cancer | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-21 | — | — | US | claimed |
| EP-1169038-A4 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2004-10-13 | — | — | EP | claimed |
| US-20040077875-A1 | (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2 -thiazolyl)carbamic Acid, 1,1-dimethylethyl ester for example; treating immunological and oncological disorders such as inflammatory bowel disease or cancer | DAS JAGABANDHU (US) | 2004-04-22 | — | — | US | claimed |
| US-20040073026-A1 | Autoimmune diseases; anticancer agents | DAS JAGABANDHU (US) | 2004-04-15 | — | — | US | claimed |
| US-20040054186-A1 | Cyclic protein tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-18 | — | — | US | claimed |
| US-20040024208-A1 | Drugs such as (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2-thiazolyl)carbamic acid, 1,1-dimethylethyl ester, used as enzyme inhibitors, for prohylaxis of inflammatory bowel disease; modulation of immunology | DAS JAGABANDHU (US) | 2004-02-05 | — | — | US | claimed |
| US-6596746-B1 | protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders; dasatinib | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-22 | — | — | US | claimed |
| EP-1169038-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-01-09 | — | — | EP | claimed |
| WO-2000062778-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB CO. (US) | 2000-10-26 | — | — | WO | claimed |
| US-20190210986-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-07-11 | — | — | US | disclosed |
| US-20190210986-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-07-11 | — | — | US | disclosed |
| EP-2960341-B1 | NOVEL TISSUE PROTECTIVE ERYTHROPOIETIN RECEPTOR (NEPOR) AND METHODS OF USE | MOLECULAR HEALTH GMBH (DE) | 2018-06-27 | — | — | EP | disclosed |
| US-20180016247-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-18 | — | — | US | disclosed |
| US-6979694-B2 | Drugs such as (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2-thiazolyl)carbamic acid, 1,1-dimethylethyl ester, used as enzyme inhibitors, for prohylaxis of inflammatory bowel disease; modulation of immunology | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-27 | — | — | US | disclosed |
| US-20050261305-A1 | Reacting 4-(2-hydroxyethyl)piperazine and 2-((2-methyl,6-chloro-pyrimidin-4-yl)-amino),5-(2-chloro,6-methyl-phenyl)thiazole to obtain 2-((2-hydroxyethyl)piperazin-4-yl)-(2-methylpyrimidin-6,4-ylene)amino-),5-(2-chloro,6-methyl-phenyl)thiazole; antiarthritic,-tumor, -carcinogentic agents; immunology | DAS JAGABANDHU | 2005-11-24 | — | — | US | disclosed |
| US-20040209930-A1 | Synergistic methods and compositions for treating cancer | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-21 | — | — | US | disclosed |
| US-6596746-B1 | protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders; dasatinib | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073026-A1 | Autoimmune diseases; anticancer agents | LCK, SSB, JAK1 | LCK 1/4885MAPK14 110/4885FYN 201/4885 |
| US-20180016247-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | LCK 1/4885MAPK14 183/4885FYN 85/4885 |
| US-20040077875-A1 | (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2 -thiazolyl)carbamic Acid, 1,1-dimethylethyl ester for example; treating immunological and oncological disorders such as inflammatory bowel disease or cancer | JAK1, LCK, MERTK | LCK 2/4885MAPK14 120/4885FYN 221/4885 |
| US-20190210986-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | LCK 1/4885MAPK14 183/4885FYN 85/4885 |
| US-20040024208-A1 | Drugs such as (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2-thiazolyl)carbamic acid, 1,1-dimethylethyl ester, used as enzyme inhibitors, for prohylaxis of inflammatory bowel disease; modulation of immunology | TPMT, JAK1, CHUK | LCK 20/4885MAPK14 232/4885FYN 623/4885 |
| US-20040209930-A1 | Synergistic methods and compositions for treating cancer | IGF1R, CHEK2, MCL1 | LCK 333/4885MAPK14 2007/4885FYN 1395/4885 |
| US-20050261305-A1 | Reacting 4-(2-hydroxyethyl)piperazine and 2-((2-methyl,6-chloro-pyrimidin-4-yl)-amino),5-(2-chloro,6-methyl-phenyl)thiazole to obtain 2-((2-hydroxyethyl)piperazin-4-yl)-(2-methylpyrimidin-6,4-ylene)amino-),5-(2-chloro,6-methyl-phenyl)thiazole; antiarthritic,-tumor, -carcinogentic agents; immunology | JAK2, JAK1, TYK2 | LCK 11/4885MAPK14 163/4885FYN 761/4885 |
| US-20040054186-A1 | Cyclic protein tyrosine kinase inhibitors | LCK, ABL1, BTK | LCK 1/4885MAPK14 183/4885FYN 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.